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Abstract
Introduction: A large proportion of women around the world suffer from chronic diseases including mental health
diseases. In the United States alone, over 12% of women of reproductive age suffer from a chronic medical
condition, especially diabetes and hypertension. Chronic diseases significantly increase the odds for poor maternal
and newborn outcomes in pregnant women.
Methods: A systematic review and meta-analysis of the evidence was conducted to ascertain the possible impact
of preconception care for preventing and managing chronic diseases and promoting psychological health on
maternal, newborn and child health outcomes. A comprehensive strategy was used to search electronic reference
libraries, and both observational and clinical controlled trials were included. Cross-referencing and a separate
search strategy for each preconception risk and intervention ensured wider study capture.
Results: Maternal prepregnancy diabetic care is a significant intervention that reduces the occurrence of
congenital malformations by 70% (95% Confidence Interval (CI): 59-78%) and perinatal mortality by 69% (95% CI:
47-81%). Furthermore, preconception management of epilepsy and phenylketonuria are essential and can optimize
maternal, fetal and neonatal outcomes if given before conception. Ideally changes in antiepileptic drug therapy
should be made at least 6 months before planned conception. Interventions specifically targeting women of
reproductive age suffering from a psychiatric condition show that group-counseling and interventions leading to
empowerment of women have reported non-significant reduction in depression (economic skill building: Mean
Difference (MD) -7.53; 95% CI: -17.24, 2.18; counseling: MD-2.92; 95% CI: -13.17, 7.33).
Conclusion: While prevention and management of the chronic diseases like diabetes and hypertension, through
counseling, and other dietary and pharmacological intervention, is important, delivering solutions to prevent and
respond to women’s psychological health problems are urgently needed to combat this leading cause of
morbidity.
Introduction
Preconception care for women with underlying chronic
diseases is very crucial. Worldwide, 60 million women of
reproductive age have type-2 diabetes [1]. While diabetes
has known macro- and micro-vascular complications,
this increasing prevalence in women of reproductive age
makes it a serious health concern for those to-be mothers
and their newborns. Diabetes during pregnancy is asso-
ciated with increased risk for miscarriages, stillbirth,
macrosomia and obstetric complications, intrauterine
developmental and growth abnormalities, birth and neo-
natal complications [2,3]. Strict control of blood glucose
during pregnancy is necessary, however counseling, diet
modification and tight glycemic control in the precon-
ception period offer a greater benefit to maternal and
newborn outcomes.
Thyroid disease is another prominent chronic illness in
women of child-bearing age, second only to diabetes. Thyr-
oid hormone imbalances during pregnancy, particularly
during the first trimester, are known to cause intellectual
impairment of the offspring as well as pregnancy complica-
tions including hypertension and preeclampsia, placental
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abruption, anemia, postpartum hemorrhage, preterm birth,
low birth-weight and fetal death [4].
Phenylketonuriais an important metabolic disorder
that has been associated with neurological sequelae and
congenital heart defects in neonates if levels of phenyla-
lanine are not controlled during pregnancy [5]. There-
fore, the most favorable period to achieve control is
before conception.
Other than the physical health of women of child bear-
ing age, their mental health is equally important in ensur-
ing healthy outcomes for both mother and child. Mood
and anxiety disorders are highly prevalent among women
of reproductive age and there is evidence that new-onset
illness or a relapse is highly prevalent during pregnancy
[6]. Psychiatric disorders during pregnancy have been
associated with poor obstetric outcomes, higher risk of
postpartum psychiatric illness, increased rates of sub-
stance abuse, and lower participation in prenatal care
leading to adverse infant outcomes [7,8]. Intimate partner
violence (IPV) has serious consequences for women’s
psychological and physical health. Victims of IPV are at
high risk of unplanned pregnancy due to sexual coercion.
Prior to taking on the challenge of supporting another
life, women should be in their optimal physical and psy-
chological health. This paper highlights the maternal
and fetal risks from uncontrolled chronic diseases and
potential interventions that have been effective in alle-
viating these risks. This paper has also assessed the risks
associated with psychological health and IPV in particu-
lar and the interventions that have met with some suc-
cess in dealing with these.
Methods
This paper systematically reviewed all the literature pub-
lished up to 2011 to identify studies describing the effec-
tiveness of preconception interventions (any intervention
provided to women and couples of childbearing age,
regardless of pregnancy status or desire, before preg-
nancy or between two pregnancies, to improve health
outcomes for women, newborns and children period
before pregnancy and between pregnancies) and risks
for preventing and managing chronic diseases and pro-
moting psychological health for improved maternal,
newborn and child health (MNCH) outcomes. Electro-
nic databases such as PubMed, Cochrane Libraries,
Embase, and WHO Regional Databases were searched
to identify the experimental and observational studies
on the subject. Papers were also identified by hand
searching references from included studies. No language
or date restrictions were applied in the search. The find-
ings were presented at international meeting [9,10] and
shared with professionals in the relevant fields of mater-
nal and child health, following which results were
updated based on current searches (through end of
2012) and expert opinion. Studies were included if they
reported the effectiveness of interventions for preventing
and managing chronic diseases and promoting psycholo-
gical health on MNCH outcomes. The methodology is
described in detailed elsewhere [11].
Two authors assessed the eligibility of studies and
extracted data and judged the quality on standardized
sheets. The quality of experimental studies were assessed
using Cochrane criteria [12], whereas STROBE guidelines
were used to assess the quality of observational studies
[13]. We conducted meta-analyses for individual studies
and pooled statistics was reported as the odds ratio (OR)
and relative risk (RR) between the experimental and con-
trol groups with 95% confidence intervals (CI). Mantel–
Haenszel pooled RR and corresponding 95% CI were
reported or the Der Simonian–Laird pooled RR and corre-
sponding 95% CI where there was an unexplained hetero-
geneity. All analyses were conducted using the software
Review Manager 5.1 [14]. Heterogeneity was quantified by
Chi2 and I2, in situations of high heterogeneity, causes
were explored through sub-group analysis and random
effect models were used.
Results
The review identified 2065 papers from search in all
databases. After the initial title and abstract screening,
187 full texts were reviewed to identify papers which
met the inclusion criteria and had the outcomes of our
interest. One hundred and sixty one studies were finally
selected for abstraction and analysis (Figure 1). Informa-





Diabetes continues to be an ever-increasing global pro-
blem. The prevalence of Type 2 (characterized by hyper-
glycemia in the context of insulin resistance and relative
lack of insulin) diabetes continues to increase worldwide
[15,16], especially in the low and middle income coun-
tries (LMICs) [17,18]. This in turn means more women
of reproductive age in LMICs have diabetes, hence a
greater number of pregnancies are complicated by the
condition [19,20] putting both the mother and the fetus
at an increased risk of morbidity and mortality [21].
Diabetes in pregnancy is associated with elevated rates
of miscarriage [22], pre-eclampsia [23,24], preterm labor
and caesarean sections [25,26] and higher rates of fetal
malformation [2,3,25,27] neural tube defect, urinary
tract disorder, macrosomia [28,29], birth injury
[26,27,30], and perinatal mortality [31,32].
Preconception diabetic care is a multidisciplinary
approach with the goal of care being to obtain the lowest
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possible hemoglobin A1C without significant episodes of
hypoglycemia. The content for preconception care broadly
includes educating the patient with regards to the disease
and its interplay with pregnancy; educating the patient
about self-management skills; physician-directed assess-
ment and care of the disease and complications; counseling
about diet, exercise and reproductive advice.
The review identified 22 observational studies [32-53]
and one trial [54] that looked at various outcomes
related to pre-gestational diabetes. Meta-analysis of 21
studies showed that preconception care was able to
reduce the occurrence of congenital malformations (RR
0.30; 95% CI: 0.22-0.41) (Figure 2). Pooled data for the
effect of preconception care on the risk of perinatal
mortality was also significant (RR 0.31; 95% CI: 0.19-
0.53) with counseling plus strict glycemic control lead-
ing to a 71% reduction in the events in this group com-
pared to the standard antenatal care group (Figure 3).
When looking at pregnancy complications, the meta-
analysis supported the effectiveness of preconception
care in non-significantly reducing the rate of preterm
delivery (RR 0.83; 95% CI: 0.62-1.12) and of caesarean
sections (RR 0.97; 95% CI: 0.77-1.23) [39,41,48,50,53].
Results for other fetal/neonatal outcomes [53] and
macrosomia [48,50,51] were also non-significant. The
data revealed that preconception care was valuable in
significantly dropping the level of HbA1C during the
first trimester of pregnancy (MD -1.71; 95% CI: -2.72,-
0.71) [32-34,38,40,45-47,55,56]. As hyperglycemia during
the period of organogenesis leads to an increased risk of
congenital malformations, this achievement of better gly-
cemic control in the 1st trimester may explain the concur-
rent reduction of anomalies as well as subsequent
perinatal death. A single study by Heller et al. [54] showed
a weak non-significant effect of preconception insulin in
reducing the 1st trimester HbA1C as compared to com-
mencement of insulin in early pregnancy (MD -0.10; 95%
CI: -0.27, 0.06).
Epilepsy management
Epilepsy is a condition in which a disruption of the nor-
mal electrochemical activity of the brain results in sei-
zures. Women with epilepsy during their child-bearing
years not only face the possible risk for adverse preg-
nancy outcome as a result of the teratogenic effects of
antiepileptic drugs upon [57,58] but also the potential
effect of maternal seizures on the developing fetus
[59-61]. Most women with epilepsy have no change in
seizure frequency during pregnancy but about 15-33%
report increased episodes of seizures during pregnancy
[62]. This may be due to a change in the pharmacoki-
netics of the anti-epileptic drugs [63] or due to the hor-
monal changes occurring in pregnancy [64]. Unplanned
pregnancies rates in women are high but these may be
Figure 1 Search flow diagram
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even higher in women with epilepsy because antiepilep-
tic drugs interfere with hormonal contraception [65].
Different drugs lead to different types and different rates
of anomalies, with the highest rates being associated
with valproate [66,67].
Preconception care of women with epilepsy includes a
careful revision of each case to ascertain the diagnosis, the
need for continued anti-epileptic drug therapy, selection
of suitable drugs with optimization of the dosage, and pre-
scription of folic acid to prevent neural tube defects.
We found one study [68] that assessed the effectiveness
of preconception counseling in women with epilepsy
reported that none of the 85 women who were counseled
before pregnancy had an abnormal fetus in the subse-
quent pregnancy as compared to almost 19% of the
women who did not receive any preconception counsel-
ing (as they were already pregnant) who had an abnormal
fetus (with 3 pregnancy terminations). One patient in the
counseled group had an early miscarriage, followed by a
normal subsequent pregnancy, and 1 had a preterm birth
compared to 3 preterm births in the control group. They
also showed that post-counseling 71% of women with
epilepsy used a single drug and none used >2 drugs as
compared to 32% and 20% respectively in the control
Figure 2 congenital malformations in preconception care versus non preconception care: evidence from observational study
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group. Most of the counseled women used carbameza-
pine/lamotrigine compared to the control women with
epilepsy, 41% of whom used valproate.
Management of phenylketonuria
Phenylketonuria (PKU) is caused by the deficiency of
phenylalanine hydroxylase which is required to essential
amino acids, phenylalanine (phe), to tyrosine [69]. These
women are advised to consume phe free food to live a
normal life. These women during pregnancy require
appropriate management as poor disease control is asso-
ciated with a multitude of fetal consequences like facial
dysmorphism, microcephaly, developmental delay, learn-
ing difficulties and congenital heart disease [69,70].
This review accumulated evidence from current litera-
ture on the effect of maternal PKU on the pregnancy
outcome, specifically of preconception levels of phenyla-
lanine. The review also looked for any preconception
intervention which worked in lowering the maternal,
newborn and child health (MNCH) risks associated with
poorly controlled phenyalanine levels. Preconception
care of women with PKU consists of counseling regard-
ing the fetal risks (facial malformations, growth deficits,
micorcephaly) associated with the disease, commence-
ment of a phenylalanine restricted diet, attaining safe
phenylalanine levels (100 [71] –360μmol/L [72] or
<6mg/dL [73,74] atleast 3 months before conception;
and maintaining them throughout gestation). When
counseling patients great importance has to be put on
the need for effective contraception till such safe levels
are reached.
The review identified seven studies [70,75-80]. Rouse
et al. [70] in a cohort of women with blood Phenylala-
nine levels >240umol/L found that mean phenylalanine
levels at 4 to 8 weeks gestation predicted congenital
heart defect (P<0.0001). They also found that each
abnormality increased in frequency as Phenylalanine
control was delayed. The percentage of offspring with
>3 dysmorphic features (49% overall) was related to
time of inadequate maternal Phenylalanine control
Figure 3 Perinatal mortality in preconception care versus non preconception care evidence from observational study
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(P=0.002), increasing from 19% in offspring of mothers
in control before pregnancy to 62% when control was
not achieved before 20 weeks’ gestational age. The fre-
quency of offspring with microcephaly was significantly
related to time of maternal Phenlalanine control
(P=0.001)- in women who were preconceptionally trea-
ted with good control, microcephaly occurred in only
3.6% of the pregnancies [5].
From current literature the effect of a preconception
dietary intervention was analyzed for growth of the fetus.
The analysis showed that a strict preconception diet was
significantly associated with an increment in mean birth
weight (MD 0.60; 95% CI: 0.39-0.82) and increase in head
circumference (MD 3.20; 95% CI: 2.37-4.03) compared to
no dietary restrictions [80]. Improved infant growth mar-
kers were also associated with following a strict precon-
ception diet in other studies [75,79]. Koch et al. [75]
reported that a preconception diet led to a 1st trimester
PHe level of 500umol/L compared to 641umol/L in those
on a post conception diet. Maillott et al. [76] also reported
a significant decrease in 1st trimester mean PHe level in
those on a preconception diet versus a post-conception
diet [248.8+/-86.6 compared with 493+/-289.4mol/L;
P<0.0001].
Addressing thyroid disorders preconceptionaly
Women of child bearing age may suffer from hypo- or
hyper-function of the thyroid gland, more often than not
due to an autoimmune process. Hypothyroidism during
pregnancy is known to lead to adverse maternal (gesta-
tional hypertension and pre-eclampsia [81], postpartum
hemorrhage, abortion [4] and preterm delivery [82,83]),
fetal (congenital anomalies, growth retardation [84], peri-
natal death) [82] and neonatal consequences (cognitive
disorders) [85]. Literature on the association between thyr-
oid disease during pregnancy and preterm delivery is most
abundant, with most attributed to autoimmune thyroid
disease [86-89]. Among the most frequent complications
are the hypertensive disorders of pregnancy, also reported
are spontaneous abortion and preterm delivery [90].
While literature on the effect of thyroid status on
maternal, fetal and neonatal effects is abundant, much
work still needs to be done with regards to the effect of
preconceptional thyroid status on these outcomes. Many
recommend attainment of a TSH <2.5mU/L before the
start of pregnancy. Since purely preconception literature
was unavailable, the review looked at the effect of peri-
conceptional interventions addressing adverse pregnancy
related outcomes and even those studying the effect of the
disease and treatment on MNCH outcomes. Content of
preconception care for women with thyroid disorders con-
sists of a thorough assessment of the disease status, advice
on the achievement of a euthyroid status well before con-
ception, counseling about the pregnancy-related risks
associated with thyroid dysfunction. Medications need to
be adjusted in order to have optimal thyroid function and
the importance of useful contraception should be stressed
upon till such a time.
Thyroid status at the time of conception plays an impor-
tant role. According to the study by Abalovich et al. [85]
none of the women who were euthyroid at the time of
conception experienced preterm deliveries. Mestman et al.
[91,92] underscores the importance of pre-pregnancy
counseling for hyperthyroid women and the use of contra-
ception until achievement of a euthyroid status before
conceiving. Earl et al. [93] found no interventions for the
prevention and treatment of hyperthyroidism during preg-
nancy. Their result for usage of antithyroid drugs (ATD)
was inconclusive due to the small potential risk of adverse
fetal effects of methimazole and maternal effects of pro-
pylthiouracil. Another study reports that both ATDs are
equally effective and safe in the treatment of hyperthyroid-
ism in pregnancy [94]. Periconception use of ATD was
however; shown to significantly increase the rates of
selected birth defects (Figure 4) [95].
Browne et al. [95] also reported an association of peri-
conception thyroxine and selected birth defects. Rotondi
et al. [96] conducted a trial on the preconception adjust-
ment of levothyroxine and found that it may lead to
adequate thyroid function in the 1st trimester; however
they did not look at any MNCH outcome. Results sug-
gest that in hypothyroid women anticipating pregnancy
(with serum TSH in the lower quartile of normal range),
the pre-conception adjustment of L-T4 doses may result
in adequate maternal thyroid function up to the first
post-conception evaluation [96].
Vaquero et al. [97] reported that in thyroid supplemen-
tation group (66mg of thyroid extract, started before con-
ception and continued until the 20th week) among
patients with thyroid antibodies, 13 out of 16 pregnancies
(81.2%) ended in live birth. Only one pregnancy loss
occurred among patients with a mild underlying thyroid
pathology treated with thyroid replacement therapy.
Systemic lupus erythromatoses and other
connective tissue diseases
Systemic lupus erythematous (SLE) predominantly affects
women in the childbearing age group, and thus the effect
of pregnancy on the disease and vice versa is an impor-
tant consideration in the management of these patients.
Despite all the advances in understanding the disease
pathology and management options pregnancy in lupus
is still considered to be a high-risk pregnancy [98]. There
is a higher rate of fetal loss, pre-term delivery and IUGR
in lupus pregnancies [98-100]. Pre-existing hypertension
or renal dysfunction further increases the risk of pre-
eclampsia and pregnancy-induced hypertension (PIH)
[100-102]. Several studies have found the frequency of
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fetal loss to vary between 11-24% [99,103-106]. While
some studies advocate that active disease increases the
risk of fetal loss [104,107,108], other studies show no sta-
tistically significant difference between pregnancies in
women with active lupus and those in women with inac-
tive lupus [109,110]. Active disease at conception is a
known predictor of poor outcome [102,109,111]. A flare
during the year prior to conception pointed to increased
risks of a flare again during pregnancy [112,113].
SLE is a prime example of an autoimmune disorder. The
review used this disease to study the possible effects of
autoimmunity on MNCH outcomes. The review also
looked at the effects of treatment modalities for SLE and
how, if any available intervention (like counseling, beha-
vioral programs) targeting such women improved the
pregnancy outcomes.
The review found a number of observational studies
looking at the effect of active disease in the preconception
period on pregnancy related outcomes [77,102,108,109,
114-128]. The analysis showed that preconception active
SLE was associated with multiple maternal and fetal/neo-
natal outcomes. An active disease increased the risks of
gestational flares by 77% (P 0.04) (Figure 5) [117,123,
125-127]. There was an over three-fold increase in the risk
of developing PIH if the disease was active (specifically
with nephritis) before pregnancy (p=0.002); no association
was found with risk of preeclampsia. There was also a sig-
nificant rise in the preterm deliveries if the disease was not
in remission before conception (RR 1.71; 95% CI: 1.18-
2.48); this risk was further increased by 13% if the woman
suffered from active nephritis pre-pregnancy.
Coming to adverse SLE related fetal/neonatal out-
comes, it was seen that a positive disease activity in the
preconception period significantly increased perinatal
mortality (RR 2.42; 95% CI: 1.06, 5.51) (Figure 6)
[102,108,117,123,125,127,128]. No association was seen
with either spontaneous abortions (RR 3.26; 95% CI:
0.58-18.14) [108,123] or restricted fetal growth (RR 0.61;
95% CI: 0.16-2.28) [127]. Similar findings were reported
by Smyth et al. [129].
Other chronic conditions
Chronic hypertension and heart disease – pregnancies
complicated by chronic hypertension are associated with
increased risk of hypertensive disorders of pregnancy
and other organ dysfunctions as well as increased fetal
risks of preterm birth, intrauterine growth retardation,
fetal loss, hypospadias and abruption placenta [130].
Romunstad et al. [131,132] found a significant association
between prepregnancy systolic as well as diastolic blood
pressure and low birth weight (LBW). Magnussen et al.
[133] found systolic blood pressures of greater than
130mmHg to increase the risk of pre-eclampsia by more
than 7 times. Because there is an increasing burden of
unplanned pregnancies, fetal exposure to antihypertensive
medications might occur before a woman knows she is
Figure 4 Periconception use of anti-thyroid medications and Birth defects evidence from observational study
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pregnant. Caton et al. [130] studied the effect of pericon-
ception use of anti-hypertensives and found a positive asso-
ciation with the occurrence of hypospadias (OR 1.90; 95%
CI: 1.00-3.61) [130], with a non-significant increase with
exposures only to antiadrenergic agents at any time
between 1 month preconception and the fourth month of
pregnancy. Hameed et al. [134] found an increased risk of
spontaneous abortion, cardiac anomaly (4-14%) in the pre-
sence of maternal congenital heart disease (CHD).
Asthma - Research demonstrates that women with
severe asthma prior to pregnancy is more likely to worsen
during pregnancy. This reinforces the importance of ade-
quate asthma control prior to conception [135]. Asthma
that is not adequately controlled during pregnancy can
result in serious maternal complications (preeclampsia,
hypertension, and hyperemesis gravidarum) [136] as well
as increased fetal complications (stillbirth and infant
death, neonatal hypoxia, intrauterine growth retardation,
premature birth, and LBW) [137]. It is observed that the
dangers of uncontrolled asthma are greater than the risks
of indispensable asthma medications. Whereas oral corti-
costeroid use in the first trimester has been associated
with reduced birth weight, an increased risk of preeclamp-
sia, and an increased risk of oral clefts [138,139]. Analysis
showed that periconception use of asthma medications
was significantly linked to a greater risk of gastroschisis
(OR 2.12; 95% CI: 1.39-3.24) [140] especially the use of
bronchodilators which significantly doubles the risk.
Chronic renal disease- Adverse pregnancy outcomes
associated with maternal renal disease include preeclamp-
sia, anaemia, chronic hypertension, caesarean delivery,
preterm delivery, fetal growth restriction, and increased
fetal loss and stillbirth [141,142]. Renal hypertension is
associated with a 10-fold increase in fetal loss compared to
women with spontaneously or therapeutically normal
blood pressures [143].
Headache – frequent pre-pregnancy headaches were
found to be statistically significantly associated with
poor mental health in the first 3 months of gestation as
well as with antepartum depression [144].
Multiple sclerosis - Vukusic et al. 2004 [145] reported
that women with greater disease activity in the year before
pregnancy have a higher risk of relapse in the postpartum
3 months (OR 1.3, p 0.04).
Figure 5 Preconception disease activity and disease flares during pregnancy evidence from observational study
Figure 6 Preconception disease activity and perinatal mortality evidence from observational study
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Medication use
Medication usage among pregnant women and women
of reproductive age is common. It has been estimated
that more than 80% of pregnant women take over-the-
counter or prescription drugs during pregnancy [146].
National surveys among women of reproductive age
document that chronic conditions often requires the
ongoing administration of medications for maintenance
are not uncommon among women of reproductive age
[147]. As maternal age and body mass index increases,
it is likely that an even greater proportion of women
who are planning a pregnancy or who could become
pregnant will have chronic diseases that necessitate pre-
scription medications. Generally, medication carries a
risk of unwanted side-effects which may have profound
impacts during pregnancy.
The aim was to look for studies assessing interventions
dealing with the repercussions of various medications
being frequently used by women. Regular medications
being used by women suffering from chronic diseases are
covered in the sections of their respective disorders. Stu-
dies particularly addressing the deleterious effects of
medications, on the health of both the mother and the
fetus, when taken in the period before conception were
assessed. The review found studies assessing the effect of
use of weight-loss drugs, oral contraceptives and vasoac-
tive agents.
Weight loss drugs - Analysis of the effect of pericon-
ception use of weight-loss drugs showed a significant
association with overall higher rates of congenital anoma-
lies (OR 1.59; 95% CI: 1.33-1.89) [148]. This association
was stronger for congenital heart defects with an 88%
increase in incidence of Dextro-Transposition of the
great arteries and a 58% increase in the incidence of Left
Ventricular Outflow Tract Obstruction (LVOTO) (OR
1.88; 95% CI: 1.33-2.65); (OR 1.58; 95% CI: 1.22-2.04)
respectively. Bitsko et al. [148] reported the association
with ‘Aortic Stenosis’ to be highest among the LVOTO
defects (OR 1.2; 95% CI: 0.5-3.1).
Oral contraceptive pills (OCPs) – several studies
identified that reported OCPs and maternal and fetal out-
comes [133,149-151] No significant association was found
between pre/peri-conception use of oral contraceptives and
gestational hypertension [150], pre-eclampsia [133,150],
preterm delivery, spontaneous abortion (Figure 7), however
periconception use of oral contraceptive pills (OCP) lead
to an almost three-fold increase in the risk of Down’s in
infants (RR 2.71; 95% CI: 1.48-4.95) [151].
Vasoactive substances - Werler et al. [152] reported
aspirin use in the periconception period led to a signifi-
cantly greater risk of amniotic bands (OR 2.5; 95% CI:
1.4-4.6). Vasoconstrictor and decongestant use led to a
higher incidence of transverse limb defects (OR 1.4; 95%
CI: 1.1-2.0) and (OR 1.7; 95% CI: 1.2-2.3) respectively.
Anti-hypertensive medications - Caton et al. 2008
[130] observed slight to moderate elevations in the risk
of severe hypospadias for maternal untreated hyperten-
sion (OR 2.1; 95% CI: 1.6-2.9) and antihypertensive
medication use during 1 month preconception through
pregnancy month 4 (OR 1.4; 95% CI: 0.7-2.9).
Bronchodilators – Lin et al. 2008 [140] reported signif-
icant association of maternal bronchodilator use with gas-
troschisis (OR 2.06, 95% CI: 1.19, 3.59).
Thyroxin – Few studies [95,96,153] reported non-
significant association with birth defects (OR 1.7; 95%
CI: 1.0-2.7).
Any illness/common cold - A study by Krapels et al.
2006 [154] displayed an association of any maternal illness
and common cold in periconception period (3 months
before conception to 3 months after) with orofacial
defects. Cleft lip with or without cleft palate increases by
1.7 times (95% CI: 1.2-2.5) and cleft palate only by
1.5 times (95% CI: 0.8-2.6).
Mental health
With the current prevalence of psychiatric illnesses,
there is a significant risk of women’s antenatal and post-
partum periods being made difficult with the onset or
recurrence of a psychiatric illness. Evidence suggests
that depression and anxiety during pregnancy and post-
partum severely impact family life, the mother-infant
relationship, and the future mental health of the child
[6-8,155]. A large meta-analysis stated that up to 18% of
women experience depressed mood during pregnancy
[156]. A Brazilian study noted that common mental dis-
orders, in general, were autonomously related with LBW
and post-traumatic disorder (PTD) in pregnant teen-
agers javascript:newshowcontent(’active’,’references’);
[157]. Maternal antenatal depression generally has been
highly correlated with PTD [158-160]. Similarly, depres-
sion also appears to be a significant risk factor for LBW
[159,161,162]. Depression also has noteworthy associa-
tions with miscarriage, antepartum hemorrhage, greater
uterine artery resistance and a higher risk of operative
deliveries [161]. Additional risks are associated with the
medications being used to treat depression. Selective
serotonin reuptake inhibitor (SSRIs) has been linked
with earlier gestational age and lower birth rate
[163,164]. Other studies also suggest first trimester
exposure to SSRIs increasing the risks restricted fetal
growth [165,166].
Bipolar disorder is a severe recurrent illness that is asso-
ciated with high rates of morbidity and mortality in the
absence of adequate treatment. Manic episodes may be
associated with increased risky behaviors such as sexual
activity or substance use, which could affect health during
pregnancy as well as lead to a significant risk of unin-
tended pregnancies [167]. Patients with bipolar disorder
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have a very high risk of comorbid alcohol or substance
abuse disorders – reaching up to 60% in some studies -
which could have direct adverse impacts on fetal outcomes
[168,169].
The review assessed the effect pre-existent psychiatric
conditions in women in the preconception period on
maternal and fetal morbidity and mortality. Included
were more prevalent conditions like mood disorders as
well as conditions like schizophrenia. The review looked
primarily at the risks and benefits, to the mother as well
as her unborn child, of continuing or changing or even
discontinuing the psychotropic regimens for the above
mentioned disorders.
While the effect of psychiatric conditions and their
relative treatment during pregnancy has been widely
studied [170-189], there is a serious lack of evidence of
how pre-pregnancy disease and psychotropic drugs may
affect pregnancy. The review found that pre-pregnancy
depression is significantly related to preterm births (OR
1.04; 95% CI: 1.02-1.07) [171] and adolescent depression
per say was significantly associated with an increased
risk of miscarriages (OR 2.25; 95% CI: 1.12-4.50) [172].
When assessing for maternal morbidity, adolescent
depression was positively associated with suffering from
intimate partner violence (IPV) (OR 3.47; 95% CI: 1.11-
10.84) but not with sexually transmitted infections
(STIs) (OR 1.50; 95% CI: 0.83-2.72) [172]. Silverman et
al. [173] concluded that a pre-existing psychiatric condi-
tion was one of the best predictors of development of
post-partum depression. Literature also showed that a
pre-pregnancy psychotic or bipolar illness substantially
increased the risk of a postpartum psychotic or bipolar
event [174]. The search for the effect of maternal
bereavement on neonatal/infant health revealed that loss
of a close relative in the 7-12 months before conception
did not increase the risks of autism, epilepsy or febrile
seizures in the infant. However, loss of a child or spouse
in the 6 months preceding conception was positively
associated with attention deficit hyperactivity disorder
(ADHD) in the male child, childhood obesity and conge-
nital malformation.
Interventions specifically targeting women of reproduc-
tive age suffering from a psychiatric condition show that
group-counseling [175] and interventions leading to
empowerment of women have reported lowering of
depression in these women but the results so far have not
Figure 7 Pregnancy outcomes of Pre/Periconception use of oral contraceptives evidence from observational study
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been significant (economic skill building: MD -7.53; 95%
CI: -17.24, 2.18; counseling: MD-2.92; 95% CI: -13.17,
7.33) [176]. Interventions teaching coping skills or based
on stepwise facilitation seem to significantly lower depres-
sion levels and these lowered levels were persistent at the
1-yr follow-up [177]. However, morbidities associated with
depressions are higher (Figure 8).
Women with serious mental illnesses are at a greater
risk of having had >1 sexual partner or having been
raped and are hence more likely to have unplanned,
unwanted pregnancies [190]. Their support system has
been reported to be generally lacking [191]. They have a
greater possibility of engaging in risky behavior during
pregnancy (substance abuse, suicide attempts) or of
being abused [192]. All this makes it imperative for
their physicians to not only screen vigorously for such
cases but also to provide comprehensive family planning
and contraceptive counseling as well as attach them to
relevant support systems.
Intimate partner violence
Irrespective of demographics, women around the globe
have been subjected to IPV. IPV against women is a
major public health concern as it adversely affects both
the physical, mental and reproductive health of a
woman and that of the newborn. physical abuse by a
partner at some point in life was reported by 13–61% of
women of 49 years of age and sexual violence by a part-
ner was reported by 6–59% of them [190]. Violence
during pregnancy has been associated with poor health
outcomes including increased risk of preterm labor [191],
antepartum hemorrhage [192], LBW infants [191], fetal
loss [193-195], STIs [196] and post-partum depression
[197]. Coker et al. [198] reported that women who
‘ever experienced’ IPV were more than twice as likely
to suffer from various kinds of physical and mental
health problems. Having experienced IPV is associated
with a higher occurrence of unwanted pregnancies
[199-201], gynecologic morbidity [202-204] and invol-
vement in risky sexual behaviors [202,204,205]. Data
suggests that intensive advocacy interventions may
improve the quality of life where as brief advocacy
interventions improve safe behaviors [206].
The content of preconception care for women suffering
from IPV includes firstly identifying such women, which
can be effectively done by asking all women about their
experiences of violence from any source, at any point in
life. Their condition needs to be evaluated and their inju-
ries treated. Women suffering from IPV need to be
informed about the significant harm to the mother, the
fetus, and the newborn infant that such abuse can poten-
tially cause and hence of the crucial role of contracep-
tives. They need be counseled for the psychological
trauma that they’ve suffered from. Finally they need to be
referred to an agency/support group that specializes in
dealing with such cases. Sexual violence specifically in
adolescents is dealt with in the section on ‘Adolescents’
(Reference to paper on adolescent health).
Figure 8 Morbidities associated with depression in adolescents: evidence from observational study
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Majority of the reviewed studies on effect of IPV
exposure were in women in the general population and
were risk aversion studies [191-197,200-205,207-242],
while few were intervention studies [176,177,243-253].
From the analysis it was found that IPV positively led to
unintended pregnancies (OR 2.33; 95% CI: 1.25-4.34)
(Figure 9) [215,218].
No association was found between IPV and condom use
in women [196,202,218]. A significant increase in gyneco-
logic morbidities was reported in women suffering from
IPV (OR 1.45; 95% CI: 1.13-1.85) [196,203] and rates of
STIs were non-significantly raised by around 2 folds in
these women (RR 1.89; 95% CI: 0.65-5.47) [202,233].
Gynecologic morbidity increased significantly with any
spousal abuse (OR 1.89; 95% CI: 1.23-2.91); combined
physical plus sexual violence led to a 72% increase (P 0.04).
With regards to a woman’s physical and mental health,
IPV had serious detrimental effects in those abused. Ruiz
et al. [254] reported that women who had experienced
physical, psychological and sexual violence were twice as
likely to suffer a chronic disease as those who have not
experienced abuse (OR 2.03; 95% CI: 1.18-3.51), especially
diseases other than hypertension, diabetes and asthma
(OR 2.57; 95% CI 1.38-4.77) [229], and fetal loss [193].
IPV leads to a towering five-fold increase in depression
among the victims (P<0.00001) (Figure 10) [222,224] and
a two-fold increase in impairment of mental health in the
past month only (RR 2.08; 95% CI: 1.70-2.55) [232,233].
Abuse also makes these women 7 times more likely to
contemplate suicide [222].
Interventions targeting IPV have mainly looked at beha-
vioral therapies. These studies have yielded non-significant
effects on the occurrence of new events of violence post-
treatment. A meta-analysis of 4 trials comparing cognitive
behavior therapy (CBT) versus no intervention showed a
reduction favoring the intervention group [234]. Behavioral
couple’s therapy, when compared to gender specific treat-
ment, showed greater reductions in post-treatment aggres-
sion and recidivism rates, especially multiple couple’s
group sessions. A dual intervention targeting both IPV
and substance abuse showed decreased rates of both in
the intervention group (RR 0.71; 95% CI: 0.37-1.38) [188].
Interventions focusing on empowerment of women
have been employed to reduce these risks, but their role
in decreasing the rate of IPV have so far not been signif-
icant. A pilot on the effectiveness of an intervention to
reduce male partner reproductive coercion was asso-
ciated with a large reduction in pregnancy coercion
among women who had recently experienced IPV (OR:
0.29; 95% CI: 0.09-0.91) [255].
Discussion
Preconception care (diet and exercise counseling, and a
stringent glycemic control) for women with preexisting
diabetes is effective in addressing the ever-increasing
rates of adverse fetal consequences (congenital malforma-
tion, perinatal mortality) as well as serious maternal out-
comes (preterm labor, level of maternal HbA1c in the
first trimester of pregnancy). This review identified signif-
icant impact of preconception diabetic care on reducing
congenital malformation and perinatal mortality. This
finding is in line with the results of some previous
reviews [25,256] with the differences being attributed to
inclusion of studies with a low to moderate level of bias.
The problem however lies in the fact that a substantial
number of women with diabetes do not access such pre-
conception care interventions and continue to have
unplanned pregnancies with deleterious MNCH results.
Figure 9 IPV and risk of unintended pregnancies (in women who have undergone IPV in the last 1 year: evidence from observational study
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Since less than 30% of those with diabetes present for
preconception care, every office visit of every female dia-
betic adolescent or woman of childbearing age should be
regarded as a preconception care visit. Also with more
women having children in their later years, screening for
type 2 diabetes among women of childbearing age
becomes more important. Future research, however,
needs to aim at evaluating the effectiveness of preconcep-
tion care on the incidence of other MNCH outcomes like
caesarean sections, spontaneous abortions, via proper
trials. What it needs more is to find ways of successfully
integrating preconception care into the routine care of all
women of reproductive age suffering from diabetes.
On the other hand, preconception management is the
cornerstone for epilepsy care in women with epilepsy.
What is recommended is a multidisciplinary approach,
involving the patient’s primary care physician, an obstetri-
cian who specializes in high-risk pregnancies, and a neu-
rologist. Women with epilepsy should be reviewed before
planning a pregnancy in order to optimize therapy before
conception. Ideally changes in antiepileptic drug therapy
should be made at least 6 months before planned concep-
tion, if possible. All women with epilepsy should be per-
suaded to begin folic acid supplementation during
reproductive years and continue throughout pregnancy. A
recent survey [257] reported that women with epilepsy are
not getting the advice they need on issues relating to con-
traception and pregnancy. This point was also conformed
in another study [258] which showed that physicians
managing women with epilepsy did not place adequate
emphasis on preconception care. The current evidence for
preconception counseling is encouraging but not conclu-
sive and requires further thorough investigation. Effective
elements of counseling or mode of delivery need to be
identified via future research. Trials should be conducted
to evaluate the value of counseling or other behavioral
interventions in the preconception period in reducing
clinically relevant outcomes. While there is an extensive
support for the pre-conception counseling of all women of
child-bearing years suffering from epilepsy, there is a
dearth of evidence evaluating the efficiency of such an
intervention in dealing with adverse pregnancy outcomes
of the disease and its treatment.
Given the complications of the maternal PKU syndrome,
a systematic approach to those intending to get pregnant
is required. The analysis revealed a significant positive
effect of strict dietary control in the preconception period
and improved growth parameters in the newborn. Studies
have also reported a decrement in other fetal risks asso-
ciated with the disease after attainment of an adequate
control of phenylalanine levels in the 1st trimester, brought
about by following a stringent dietary plan before preg-
nancy. There is evidence that a preconception phenylala-
nine-restricted diet works, however what is needed now is
to finalize a preconception protocol for women with PKU
and implement it on a larger scale for better coverage. An
absolute dearth of evidence was also identified in women
with thyroid dysfunction. However, logic dictates that
ensuring maternal biochemical euthyroidism in the first
trimester, when the fetus is most responsive tomaternal
thyroxine, might optimize fetal outcome. To achieve this
target those already suffering from thyroid dysfunction
Figure 10 IPV and risk depression (in women who have undergone IPV in the last 1 year: evidence from observational study
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need to be re-evaluated before they plan to conceive, their
treatment regimens need to be re-adjusted and they need
to be counseled about the probable risks to both lives that
an unachieved euthyroid status may lead to. Future
research not only needs to find the missing link between
thyroid function before conception and a fall in associated
MNCH morbidities, it also needs to focus on how to
achieve this in women with thyroid disorders who want to
conceive.
Pregnancy is safe in most lupus patients who conceive
while the disease is inactive; however pregnancy statisti-
cally increases SLE activity. Active SLE prior to preg-
nancy is associated with a less favourable maternal and
fetal outcome and conception should hence be avoided, if
possible. The analysis showed that an active disease status
in the preconception period significantly increased the
risks of gestational flares by 77%, PIH by over three folds,
preterm deliveries by twice as much and perinatal mortal-
ity by over two-folds. No association was found with pre-
eclampsia, fetal growth restriction or spontaneous
abortions. These findings highlight the importance of a
preconception intervention to address the reproductive
issues in women suffering from SLE. Similarly, several
drugs used by women with lupus have been contraindi-
cated during pregnancy for their adverse effects on
maternal and fetal outcomes.
This review of the literature found important evidence
pertaining to the periconception use of certain drugs used
regularly for chronic disorders or other purposes. Anti-
asthmatics, especially bronchodilator use, in the pericon-
ception period led to a more than two-fold increase in the
incidence of gastroschisis. Weight-loss drugs led to a 58%
increase in the risk of congenital malformations, especially
congenital heart defects. OCPs led to a non-significant
increase in various pregnancy and fetal outcomes. Vasoac-
tive substances, like aspirin, decongestants and vasocon-
strictors were associated with limb defects. It is therefore,
advisable to women to take these drugs only when pre-
scribed by doctors after thorough assessment of history
and examination of potential side effects.
Mental health conditions are prevalent among women
of reproductive age and a substantial proportion goes
untreated. Due attention is being paid to screening for
and treating psychosocial issues during pregnancy and
post-partum but non-pregnant women are being
neglected in this regard. There is a deficiency of evi-
dence associating the status of disease and treatment in
the preconception period with adverse MNCH effects.
This explains the lack of literature on effective interven-
tions targeting such women, implementation of which
would be a task of its own. Interventions already proved
efficacious in pregnancy should also be evaluated for
women before pregnancy. IPV, on the other hand, is a
serious, widely prevalent issue. Apart from being viola-
tions of human rights, acts of violence profoundly
damage the physical, sexual, reproductive, emotional,
mental and social well-being of not only individuals but
families. IPV has adverse effects on women, leading to
an increase in unplanned pregnancies, gynecologic infec-
tions and probable fetal loss Current interventions for
reducing IPV and related morbidities have mainly
looked at behavioral therapies. Behavioral couple’s ther-
apy has shown greater reductions in post-treatment
aggression and recidivism rates, especially multiple cou-
ple’s group sessions. Although these interventions may
not have shown significant effects yet, there is every rea-
son to believe that thorough outcome evaluations of
present programmes along with development of new
programs based on sound supposition and identified
risk factors will translate into a swift expansion in the
near future.
Although the review identified the impact of majority
of chronic and mental diseases on MNCH outcomes, it
was, however, unable to gather evidence on preconcep-
tion respiratory diseases such as cystic fibrosis, endo-
crine problems such as ovarian syndrome and women
with cancers. This was mainly because of dearth of lit-
erature on these topics particularly from preconception
period.
Conclusion
Provision of care to high risk women for chronic medical
conditions is as important as any other general health
promotion. Delaying and achieving optimal timing of a
pregnancy is often an important component of the pre-
conception care of women with medical conditions. Since
majority of the pregnancies are unplanned, therefore,
reproductive planning and contraceptive considerations
for women of reproductive age with chronic medical con-
ditions should be discussed early after diagnosis. IPV is a
serious, widely prevalent issue. Apart from being viola-
tions of human rights, acts of violence profoundly
damage the physical, sexual, reproductive, emotional,
mental and social well-being of not only individuals but
families. IPV has untoward effects on women, leading to
an increase in unplanned pregnancies, gynecologic infec-
tions and probable fetal loss. Abuse also leads to grave
impairment of the physical and mental health of the
victims.
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